Cargando...
Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck
Pembrolizumab and nivolumab are anti-PD-1 immunotherapy agents approved for the treatment of metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) with demonstrated benefit as shown by the CheckMate 141 and KEYNOTE-040 clinical trials. Increasing costs of anticancer drugs in particul...
Gardado en:
| Publicado en: | Am J Cancer Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
e-Century Publishing Corporation
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7339274/ https://ncbi.nlm.nih.gov/pubmed/32642293 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|